版本:
中国

最新动态: 石藥集團有限公司 (1093.HK)

1093.HK ( 香港证券交易所 )

15.46HKD
19 Sep 2019
涨跌 (%)

HK$0.18 (+1.18%)
收盘
HK$15.28
开盘
HK$15.40
当日最高
HK$15.52
当日最低
HK$15.28
成交量
15,220,724
平均成交量
36,047,466
52 周最高
HK$19.26
52 周最低
HK$9.90

最新动态 (Source: Significant Developments)

Cspc Pharmaceutical Says Recombinant Anti-Her2 & Anti-Cd3 Granted Clinical Trial Approval By U.S. FDA
2019年 9月 2日 星期一 17:01 BJT 

Sept 2 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::RECOMBINANT ANTI-HER2 & ANTI-CD3 HUMANIZED BISPECIFIC ANTIBODY FOR INJECTION GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA.  全文

CSPC Pharmaceutical Group Says New Target Anti-Tumor Drug Granted Clinical Trial Approval
2019年 7月 29日 星期一 18:00 BJT 

July 29 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::NEW TARGET ANTI-TUMOR DRUG "SYHA1807" GRANTED CLINICAL TRIAL APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  全文

CSPC Pharmaceutical Group Sees Jan-June Net Profit Attributable Increased By 12% To 30% Of Cspc Innovation Pharmaceutical Co
2019年 7月 12日 星期五 18:00 BJT 

July 12 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SEES JAN-JUNE NET PROFIT ATTRIBUTABLE INCREASED BY 12% TO 30% OF CSPC INNOVATION PHARMACEUTICAL CO.  全文

CSPC Pharmaceutical Group Says Ticagrelor Tablets Granted Drug Registration Approval
2019年 6月 13日 星期四 16:49 BJT 

June 13 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::TICAGRELOR TABLETS GRANTED DRUG REGISTRATION APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  全文

CSPC Pharmaceutical Says Clopidogrel Bisulfate Tablets Granted Drug Registration Approval
2019年 6月 10日 星期一 17:19 BJT 

June 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CLOPIDOGREL BISULFATE TABLETS GRANTED DRUG REGISTRATION APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  全文

CSPC Pharmaceutical Group Posts Qtrly Profit Attributable Of RMB951.8 Mln
2019年 5月 21日 星期二 12:05 BJT 

May 21 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::QTRLY PROFIT ATTRIBUTABLE RMB951.8 MILLION VERSUS RMB738.8 MILLION .QTRLY TOTAL REVENUE RMB5.49 BILLION VERSUS RMB4.37 BILLION .  全文

CSPC Pharmaceutical Group Posts FY Profit Attributable Of HK$3.65 Bln
2019年 3月 18日 星期一 12:01 BJT 

March 18 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::FY PROFIT ATTRIBUTABLE HK$3.65 BILLION VERSUS HK$2.77 BILLION.FY REVENUE HK$21.03 BILLION VERSUS HK$15.46 BILLION.DECLARED A FINAL DIVIDEND PER SHARE OF HK18 CENTS.  全文

CSPC Pharmaceutical Submitted New Drug Application To U.S. FDA For Levoamlodipine Maleate Tablets
2019年 3月 5日 星期二 17:58 BJT 

March 5 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SUBMITTED NEW DRUG APPLICATION TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS FOR TREATMENT OF HYPERTENSION.  全文

CSPC Pharmaceutical Says Cetrain Financial Media Reported Co Indicated 20 Pct-30 Pct Profit Growth For FY19
2019年 1月 10日 星期四 19:22 BJT 

Jan 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL SAYS CETRAIN FINANCIAL MEDIA REPORTED THAT COMPANY INDICATED A TARGET GUIDANCE OF 20%-30% PROFIT GROWTH OF GROUP FOR FY 2019.BOARD STATES THAT ANALYST REPORTS FAIRLY REFLECT CURRENT VIEW OF MANAGEMENT.  全文

CSPC Pharmaceutical Group'S Unit Enters Agreement With I-Mab Biopharma (Shanghai) Co
2018年 12月 17日 星期一 17:18 BJT 

Dec 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT ENTERED INTO AN AGREEMENT WITH I-MAB BIOPHARMA (SHANGHAI) CO., LTD..CSPC BAIKE AGREED TO PAY UPFRONT PAYMENT OF RMB15 MILLION & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB135 MILLION TO I-MAB.DEAL FOR LICENSING & COMMERCIALIZATION OF LONG-ACTING RECOMBINANT GLP-1 FC FUSION PROTEIN (TG103) FOR INJECTION DEVELOPED BY I-MAB.  全文